FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088684759> ?p ?o ?g. }

• W3088684759 endingPage "916" @default.
• W3088684759 startingPage "903" @default.
• W3088684759 abstract "Psoriasis is a common immune-mediated chronic inflammatory disease, and observations have pointed toward the IL-23/Th17 cell axis as having a key role in the pathogenesis of psoriasis. This new immunological understanding of the pathogenesis has been translated into targeted and highly effective biologic therapies. Tildrakizumab is a humanized IgG1/k monoclonal antibody targeting the p19 unit of IL-23 and has been registered for the treatment of patients with moderate-to-severe chronic plaque psoriasis in adults since 2018. This review provides an overview of the efficacy and safety of tildrakizumab, focusing on the results from clinical trials. In both Phase II and III trials, tildrakizumab 100 and 200 mg was significantly more efficacious than both placebo and etanercept at week 12. The effect of tildrakizumab continued to increase until week 28. Long-term follow-up showed high levels of efficacy for up to 3 years. Despite no difference between 100 and 200 mg in Phase III studies, subgroup analyses showed better efficacy when treated with 200 mg in patients with bodyweight ≥90 kg. The overall drug safety was good, and besides discrete higher incidence of nasopharyngitis, the conducted clinical trials show that tildrakizumab was very well tolerated without any safety concerns. Compared to other IL-23p19 inhibitors, tildrakizumab seemed to have slightly lower efficacy. However, to determine its position in the treatment algorithm of psoriasis, head-to-head trials with other IL-17, IL-12/23, and IL-23 inhibitors and long-term real-world data are required." @default.
• W3088684759 created "2020-10-01" @default.
• W3088684759 creator A5009118689 @default.
• W3088684759 creator A5029899873 @default.
• W3088684759 creator A5077648441 @default.
• W3088684759 date "2020-09-01" @default.
• W3088684759 modified "2023-10-10" @default.
• W3088684759 title "<p>Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis</p>" @default.
• W3088684759 cites W1826301003 @default.
• W3088684759 cites W1924457352 @default.
• W3088684759 cites W1975330719 @default.
• W3088684759 cites W2012608901 @default.
• W3088684759 cites W2041820695 @default.
• W3088684759 cites W2080165152 @default.
• W3088684759 cites W2099687194 @default.
• W3088684759 cites W2158420662 @default.
• W3088684759 cites W2333311307 @default.
• W3088684759 cites W2517289120 @default.
• W3088684759 cites W2561759163 @default.
• W3088684759 cites W2623888527 @default.
• W3088684759 cites W2763793357 @default.
• W3088684759 cites W2781078917 @default.
• W3088684759 cites W2789832091 @default.
• W3088684759 cites W2792924793 @default.
• W3088684759 cites W2806365218 @default.
• W3088684759 cites W2809332375 @default.
• W3088684759 cites W2899473470 @default.
• W3088684759 cites W2922099376 @default.
• W3088684759 cites W2924461089 @default.
• W3088684759 cites W2924895007 @default.
• W3088684759 cites W2925250388 @default.
• W3088684759 cites W2943251437 @default.
• W3088684759 cites W2944224722 @default.
• W3088684759 cites W2953295625 @default.
• W3088684759 cites W2967066402 @default.
• W3088684759 cites W2967437723 @default.
• W3088684759 cites W2970328992 @default.
• W3088684759 cites W2971816470 @default.
• W3088684759 cites W2977744749 @default.
• W3088684759 cites W2991659810 @default.
• W3088684759 cites W2999032467 @default.
• W3088684759 cites W3001336221 @default.
• W3088684759 cites W3005392748 @default.
• W3088684759 cites W3012045824 @default.
• W3088684759 cites W3021421518 @default.
• W3088684759 cites W4211077900 @default.
• W3088684759 cites W4237432556 @default.
• W3088684759 doi "https://doi.org/10.2147/tcrm.s227880" @default.
• W3088684759 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7522402" @default.
• W3088684759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33061395" @default.
• W3088684759 hasPublicationYear "2020" @default.
• W3088684759 type Work @default.
• W3088684759 sameAs 3088684759 @default.
• W3088684759 citedByCount "7" @default.
• W3088684759 countsByYear W30886847592021 @default.
• W3088684759 countsByYear W30886847592022 @default.
• W3088684759 crossrefType "journal-article" @default.
• W3088684759 hasAuthorship W3088684759A5009118689 @default.
• W3088684759 hasAuthorship W3088684759A5029899873 @default.
• W3088684759 hasAuthorship W3088684759A5077648441 @default.
• W3088684759 hasBestOaLocation W30886847591 @default.
• W3088684759 hasConcept C126322002 @default.
• W3088684759 hasConcept C142724271 @default.
• W3088684759 hasConcept C156730664 @default.
• W3088684759 hasConcept C159654299 @default.
• W3088684759 hasConcept C16005928 @default.
• W3088684759 hasConcept C163864487 @default.
• W3088684759 hasConcept C17991360 @default.
• W3088684759 hasConcept C203014093 @default.
• W3088684759 hasConcept C204787440 @default.
• W3088684759 hasConcept C27081682 @default.
• W3088684759 hasConcept C2776914184 @default.
• W3088684759 hasConcept C2777226972 @default.
• W3088684759 hasConcept C2780564577 @default.
• W3088684759 hasConcept C47348012 @default.
• W3088684759 hasConcept C535046627 @default.
• W3088684759 hasConcept C542903549 @default.
• W3088684759 hasConcept C71924100 @default.
• W3088684759 hasConcept C90924648 @default.
• W3088684759 hasConcept C98274493 @default.
• W3088684759 hasConceptScore W3088684759C126322002 @default.
• W3088684759 hasConceptScore W3088684759C142724271 @default.
• W3088684759 hasConceptScore W3088684759C156730664 @default.
• W3088684759 hasConceptScore W3088684759C159654299 @default.
• W3088684759 hasConceptScore W3088684759C16005928 @default.
• W3088684759 hasConceptScore W3088684759C163864487 @default.
• W3088684759 hasConceptScore W3088684759C17991360 @default.
• W3088684759 hasConceptScore W3088684759C203014093 @default.
• W3088684759 hasConceptScore W3088684759C204787440 @default.
• W3088684759 hasConceptScore W3088684759C27081682 @default.
• W3088684759 hasConceptScore W3088684759C2776914184 @default.
• W3088684759 hasConceptScore W3088684759C2777226972 @default.
• W3088684759 hasConceptScore W3088684759C2780564577 @default.
• W3088684759 hasConceptScore W3088684759C47348012 @default.
• W3088684759 hasConceptScore W3088684759C535046627 @default.
• W3088684759 hasConceptScore W3088684759C542903549 @default.
• W3088684759 hasConceptScore W3088684759C71924100 @default.
• W3088684759 hasConceptScore W3088684759C90924648 @default.

• next